Clinical trials in Leidschendam – page 66

1 919 clinical trials in Leidschendam, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Leidschendam at a glance

1 919

clinical trials

Research sites1

Quick filters

1 919 trials in Leidschendam

Open in trial search

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Genmab A/S

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atumelnant
Sponsor:Crinetics Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Muvalaplin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ioflupane (123I)
Sponsor:Biohaven Therapeutics Ltd.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Olpasiran
Sponsor:Amgen Inc.

Contact Research Centre

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Scleroderma Research Foundation

Contact Research Centre

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:BHV-7000
Sponsor:Biohaven Therapeutics Ltd.

Contact Research Centre

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pimecrolimus
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leidschendam

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatment advancements, evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

Advanced NSCLC treatments
Immunotherapy combinations
KRAS G12C inhibitors

Studies compare various treatment options to improve patient outcomes and survival rates.

02 Breast Cancer Studies

Comprehensive research into breast cancer treatments, particularly focusing on hormone receptor-positive and HER2-positive subtypes, investigating targeted therapies and chemotherapy combinations.

Metastatic breast cancer
HER2-positive therapy
Triple-negative breast cancer

Trials examine innovative treatment strategies and personalized approaches.

03 Hematologic Malignancies

Studies focusing on lymphoma treatments, including both Hodgkin and non-Hodgkin variants, evaluating response-adapted therapies and novel drug combinations.

Advanced Hodgkin Lymphoma
Follicular Lymphoma
Treatment optimization

Research aims to improve treatment outcomes while minimizing toxicity.

04 Gastrointestinal Oncology

Investigations into colorectal cancer and related conditions, including innovative surgical approaches and treatment strategies for recurrent disease.

Rectal cancer treatments
Esophagogastric cancer
Surgical innovations

Focus on improving surgical outcomes and treatment effectiveness.

05 Brain Metastases Research

Studies examining treatment options for cerebral radiation necrosis and brain metastases, including innovative detection methods and therapeutic approaches.

Radiation necrosis treatment
Metastatic detection
Targeted therapies

Research aims to improve detection and treatment of brain metastases.

Back to the Netherlands All countries